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ABSTRACT 
Objectives 
The aim of this study was to review all published economic evaluations of guideline-based care for 
chronic wounds and to assess how useful these studies are for decision making in health services. 
Methods 
Embase, PubMed, Scopus, Health Technology Assessment (HTA) and National Health Service 
Economic Evaluation Database (NHS EED) were searched on April 16th, 2018. We included studies 
that evaluated the economic impact and health outcomes associated with implementing evidence-
based guidelines as a bundle of care for the prevention and/or treatment of chronic wounds. 
Information was extracted from each eligible study and organised by the type of chronic wound. The 
quality of published economic evaluation studies was assessed using the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS). 
Results 
A total of 24 economic evaluation studies met the inclusion criteria, of which 12 applied decision 
analytic models. The compliance with the CHEERS checklist ranged between 43% and 83%. 
Limitations 
We may have missed some economic evaluation studies despite the use of broad search terms. The 
quality assessment was conducted based on judgment. Using the CHEERS checklist may reflect the 
way evaluations were reported rather than conducted. 
Conclusions and implications of key findings 
We found that guideline-based care may be cost-saving or cost-effective in most circumstances. The 
quality and usefulness of reviewed studies for decision making was variable. Better information and 
higher-quality economic evaluations will increase decision makers' confidence to promote guideline-
based care. 
Systematic review registration number 
PROSPERO CRD42017051859 
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Key Points for Decision Makers 
Providing better wound management based on guidelines may improve patient outcomes at a lower 
cost or at some acceptable additional cost. 
There are variations in the quality of reviewed economic evaluation studies, which may limit the 
usefulness of those studies to decision making. 
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1 INTRODUCTION  
Chronic wounds are skin lesions that take more than 3 months to heal [1]. The most common 
chronic wounds seen in general practice include diabetic foot ulcers (DFUs), venous leg ulcers 
(VLUs), pressure ulcers (PUs) and arterial ulcers (AUs) [2]. Chronic wounds have been described as a 
silent epidemic as they are often disguised as comorbid conditions [3]. For example, DFU is usually 
defined as a complication of diabetes. In fact, chronic wounds are affecting a large proportion of the 
world’s population. In the UK, it is estimated that 70,000–190,000 individuals have VLUs at any time 
and around 400,000 individuals develop a new PU annually[4]. In the USA, more than 6 million 
people are affected by chronic wounds [3]. The incidence and prevalence of chronic wounds will 
continue to rise, fuelled by the aging population and increasing numbers of diseases and conditions 
such as diabetes and obesity. Chronic wounds not only reduce the quality of life of affected 
individuals [5-7], but also are associated with substantial costs. In Australia, the total cost of chronic 
wounds was estimated at USD $2.85 billion annually [8], but this estimate was highly uncertain due 
to lack of Australian data on incidence of chronic wounds. In the UK, the cost of managing chronic 
wounds was conservatively estimated at £2.3–3.1 billion per year [4]. A recent study in the US 
estimated that total Medicare spending in 2014 for all wound types ranged from $28.1 to $96.8 
billion [9]. 
Clinical guidelines have been developed across the globe incorporating best available evidence to 
manage chronic wounds. The International Working Group on the Diabetic Foot has been publishing 
and updating guidance documents on prevention and management of foot problems in diabetes 
since 1999 [10]. The Australia and New Zealand clinical practice guideline for prevention and 
management of venous leg ulcers [11] summarizes best information available on the assessment, 
diagnosis, management and prevention of VLUs within the Australian and New Zealand health care 
context. The National Pressure Ulcer Advisory Panel (NPUAP), European Pressure Ulcer Advisory 
Panel (EPUAP) and Pan Pacific Pressure Injury Alliance (PPPIA) have collaborated and developed an 
international guideline on the prevention and treatment of PUs [12]. Apart from the three guidelines 
mentioned, there are many other guidelines from different organizations and countries. However, 
there is often a gap between guidelines and implementation, which can be caused by lack of 
reimbursement and incentives and poor education and training among health professionals [13]. 
Where wound care followed clinical evidence, studies have found that healing rates were improved 
and recurrence reduced [14, 15]. However, implementing guideline-based care usually incurs 
additional costs to the health system and patients, and little is known about whether the investment 
in guideline-based care can be offset or outweighed by improved healing, fewer complications or 
fewer wound recurrences.  
 Carter [16] conducted a systematic review on economic evaluations of guideline-based or strategic 
Interventions for the prevention or treatment of chronic wounds. However, some studies included in 
Carter’s review evaluated strategic interventions not relevant to published guidelines. For example, 
Carter’s review included a study by Gordon et al. [17] where authors examined the cost-
effectiveness of a community Leg Club® model for chronic VLU management compared with 
traditional community home nursing. The study, however, did not compare guideline-based care to 
standard care because participants in both intervention and control groups received comprehensive 
assessment and compression therapy. The main difference between comparators lay in the location 
of wound care rather than whether guideline-based care was implemented. Carter also limited 
eligibility to studies that included at least one incremental cost-effectiveness ratio (ICER) or 
incremental net health benefit (INHB) or provided costs and benefits so that ICERS/INHBs could be 
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calculated. But this would exclude economic evaluations conducted earlier. For example, Thomson 
et al. [18] published a pilot economic evaluation of a potential PU prevention programme in 1999 
but reported costs and benefits with a range rather than mean or median value. Thus, an explicit 
ICER or INHB could not be derived from the study. But the study still provided some evidence that 
the benefits outweighed the costs and should be considered for its usefulness to decision making. 
The aim of this study was to conduct a systematic review of published economic evaluations of 
guideline-based wound care that incorporates clinical evidence to treat and/or prevent chronic 
wounds in the adult population and to assess how useful these studies are in providing information 
for decision makers in this field. We also aimed to address some limitations presented in Carter’s 
review in our systematic review in addition to including more recently published studies. 
2 METHODS 
This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) Statement [19]. Searches were conducted in the following databases on April 
16th, 2018: Embase, PubMed, Scopus, Health Technology Assessment (HTA) and National Health 
Service Economic Evaluation Database (NHS EED). The systematic review protocol was published in 
PROSPERO (ID: CRD42017051859). Search terms used in each database were summarized in the 
Appendix. 
Studies were eligible for inclusion if they: were economic evaluation studies (cost-effectiveness, 
cost-utility or cost-benefit); evaluated the economic impact and health outcomes associated with 
implementing guideline-based recommendations (a bundle of care) for the prevention and/or 
treatment of chronic wounds. Studies were excluded if they: evaluated a single product or 
intervention for the treatment or prevention of chronic wounds; were published as conference 
abstract, letters, and editorials, note and short surveys; or were cost analyses where health 
outcomes were not evaluated. The search was not restricted to the English language nor by 
publication period. Full inclusion and exclusion criteria for selection of studies to be included in this 
review are given in the protocol published in PROSPERO (ID: CRD42017051859). 
Initial selection of studies was based on screening titles and abstracts. Full articles of potentially 
relevant studies were assessed for eligibility. Final decisions regarding the inclusion or exclusion of 
studies were made on a consensus between both reviewers (REP and QC). Reference lists of included 
studies were scanned for other potential studies. Key information from each included study was 
extracted into a data table. 
The quality of published economic evaluation studies was assessed using the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) [20]. The 24-item checklist is a consolidation and 
update of previous reporting guidelines. It consists of recommendations on reporting methods and 
findings for economic evaluation studies and provides a means of comparing studies. We used the 
CHEERS checklist not only because it has been endorsed by several journals as a guideline to report 
methods and results, but also it helps determine the usefulness of those studies to decision/policy 
makers. A simple conclusion whether a practice is cost-effective or not will not suffice as a support 
to change policies. Information on the target population, what clinical effectiveness the study relies 
on and how uncertainty impacts on the results is also required to complete the message we want to 
convey to decision/policy makers. When scoring the included studies against the CHEERS checklist, 
we used 1 for an item that met the criteria, 0.5 for item that partially met the criteria and 0 when 
the study did not meet the criteria. We also assessed overall compliance with the CHEERS checklist 
by calculating the proportion of the CHEERS criteria addressed by the study. Fully meeting the 
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criteria would contribute 1 to the numerator while partially meeting the criteria would contribute 
0.5 to the numerator. Any criteria items that were not applicable to the study were excluded from 
the denominator. 
 
3 RESULTS 
A total of 5628 records were identified through the search and additional sources. After duplicate 
removal and initial screening, 51 full articles were assessed for eligibility and 24 met the inclusion 
criteria [18, 21-43]. The reasons for exclusion are shown in Figure 1. 
Figure 1. PRISMA flow diagram showing process of study selection for inclusion in systematic review 
  
3.1 Overview of included studies 
Tables 1 – 4 summarize the data extraction from each study. Of the 24 included studies that 
evaluated the costs and health outcomes of implementing guideline-based practice for chronic 
wounds, 7 focused on DFU [21-27], 8 on PUs [18, 28-34] , 4 on VLUs [35-38] and 5 on mixed types of 
chronic wounds [39-43]. Ten studies referred to evidence-based or specialist wound care or gold 
standard care but did not explicitly mention whether the intervention was guideline-based [18, 28, 
29, 35, 36, 38-41, 43]. We still included these studies in this review, but adjusted the quality score 
accordingly. 
Economic evaluations were conducted either 1) alongside randomized controlled trials (RCTs) or 
using other study designs (referred to as “not model-based” in this paper) or 2) use economic 
modelling techniques such as decision trees and Markov models (“model-based” studies). Twelve 
out of the 24 included studies were model-based: ten studies developed Markov models [22-25, 27-
29, 31, 36, 40] and 2 studies used decision tree models [21, 30] for the analysis, but a figure 
illustrating the model structure was not provided in 2 studies [25, 29]. The remaining 12 studies 
compared the implementation of guideline-based care with non-implementation through 
prospective cohort study and retrospective data audit [26, 38, 39, 41], prospective cohort study and 
retrospective data audit [33, 37], quasi-experimental pre/post study [34, 35, 42],  cluster randomized 
trial [32, 43] or a prevalence and incidence study [18]. 
Outcome measures used in these 24 studies varied by study design. All 12 studies that applied 
models reported outcomes using incremental cost-effectiveness ratios (ICER) which were calculated 
by dividing the difference in cost between two practices by the difference in their effectiveness. 
Other studies reported change in costs and clinical outcomes either separately, or in a specific form, 
such as cost per ulcer-free day. Most studies demonstrated that implementing guideline-based care 
would be cost-saving or cost-effective except for 2 studies. Whitty et al. [32] applied cost-
effectiveness and cost-benefit analysis to evaluate a pressure prevention bundle. They found that 
net monetary benefit for the intervention was negative. Graves et al. [40] constructed a Markov 
model and compared total costs and health outcomes before and after the patients’ admission to a 
specialist wound clinic. They found that specialist wound care reduced costs but there was a very 
slight decrement in QALYs for patients receiving evidence-based wound care.  
 7 
Table 1. Summary characteristics of economic evaluation studies for DFU 
Author (Setting) Publication 
Year 
Type of care Intervention Comparator Analysis Study design Perspective Time 
horizon/ 
Study 
period 
Outcome 
measures 
Baseline 
analysis 
Sensitivity 
analysis 
Cardenas et al. 
[21] 
(Peru) 
2015 Prevention Standard care based on 
International Diabetes 
Federation guidelines 
Sub-optimal 
care 
CEA Decision tree Societal  1 year Cost per deaths 
averted 
Cost-saving Robust (OW) 
Cheng et al.[22] 
(Australia) 
2016 Prevention 
and treatment 
Optimal care based on 
National Evidence 
Based Guidelines on 
Prevention, 
Identification and 
Management of Foot 
Complications in 
Diabetes 
Usual care CUA Markov model (7 
health states) 
Health system 5 years Δcost/ΔQALY Cost-saving Robust (SA, 
PSA) 
Ortegon et al. 
[23] 
(Netherlands) 
2004 Prevention 
and treatment 
Optimal prevention 
and treatment 
according to 
International 
consensus on diabetic 
foot 
Present level of 
prevention 
CUA Markov model 
(13 health states) 
Not reported 
(health system) 
Life time Δcost/ΔQALY Cost-
effective 
Robust (OW) 
Ragnarson 
Tennvall et al. 
[24] 
(Sweden) 
2001 Prevention Optimal patient 
prevention according 
to International 
consensus on diabetic 
foot 
Present level of 
prevention 
CUA Markov model (8 
health states) 
Not reported 
(health system) 
5 years Δcost/ΔQALY Not cost-
effective 
for low risk 
group; 
cost-saving 
or cost-
effective 
for other 
risk groups 
Robust (OW) 
Rauner et al. [25] 
(Austria) 
2005 Prevention Intensified prevention 
program based on 
International 
consensus on diabetic 
foot 
Present 
prevention 
CUA Markov model (8 
health states) 
Not reported 
(health system) 
10 years Δcost/ΔQALY Not cost-
effective 
for low risk 
group; 
cost-saving 
or cost-
effective 
Robust (OW) 
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for other 
risk groups 
Rerkasem et al. 
[26] 
(Thailand) 
2009 Prevention 
and treatment 
Multidisciplinary 
Diabetic Foot Protocol 
Standard care CEA Retrospective 
data audit 
Not reported 
(societal) 
3 years 7 
months* 
Costs and SF-36 
score 
Cost-saving NA 
Wu et al. [27] 
(China) 
2018 Prevention Prevention based on 
the recommendations 
of experts and IWGDF 
guidance documents 
Usual care CUA Markov model (8 
health states) 
Healthcare Life time Δcost/ΔQALY Cost-saving Robust (OW, 
PSA) 
CUA= cost-utility analysis; CEA=cost-effectiveness analysis; QALY= quality -adjusted life-year; OW=one-way; SA= scenario analysis; PSA= probabilistic sensitivity analysis; NA= not applicable  
*Study period 
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Table 2. Summary characteristics of economic evaluation studies for PU 
Author 
(Setting) 
Publication 
Year 
Type of care Intervention Comparator Analysis Study design Perspective Time horizon/ 
Study period 
Outcome 
measures 
Baseline 
analysis 
Sensitivity 
analysis 
Bayoumi et al. 
[28] 
(Canada) 
2008 Prevention Strategy 2: alternative 
foam mattress and 4-
hourly 
turning/repositioning 
schedules 
Standard 
care 
CUA Markov model 
(52 health 
states) 
Ontario 
Ministry of 
Health  
Life time Δcost/ΔQALY Cost-effective Robust (OW, 
SA, PSA) 
Makai et al. 
[29] 
(Netherlands) 
2010 Prevention A quality 
improvement 
collaborative that 
used evidence-based 
preventive measures 
Before 
implementa
tion of 
protocol 
CUA Markov model 
(10 health 
states) 
Healthcare 2 years Δcost/ΔQALY Variable Variable (PSA) 
Mathiesen et 
al. [30] 
(Denmark) 
2013 Prevention Guideline-based 
Pressure Ulcer Bundle 
No specific 
pressure 
ulcer 
prevention 
strategy 
CEA Decision tree Public 
healthcare 
Maximum 
length of 
healing time 
for a pressure 
ulcer plus 
potential 
complication 
Δcost and 
number of 
prevented 
pressure ulcers 
and the 
number of 
saved lives 
Cost-saving Robust (OW, 
PSA) 
Padula et al. 
[31] 
(USA) 
2011 Prevention Prevention based on 
Wound, Ostomy, and 
Continence Nurses 
Society (WOCN) 
guidelines 
Standard 
care 
CUA Semi-Markov 
model (6 main 
health states) 
Societal 1 year (QALYs 
from remaining 
life expectancy 
were included) 
Δcost/ΔQALY  Cost-saving Robust (OW, 
PSA) 
Thomson et al. 
[18] 
(UK) 
1999 Prevention A potential 
prevention program 
Current care CBA Prevalence and 
incidence 
studies 
Not reported 
(health system) 
1 year* Net benefit Cost-saving Robust (OW) 
Whitty et al. 
[32] 
(Australia) 
2017 Prevention A care bundle based 
on the Institute of 
Healthcare 
Improvement 
recommendations 
and is evidence-based 
Standard 
care 
CEA & CBA Pragmatic 
cluster-
randomised 
trial 
Health system 4 weeks* cost per 
pressure ulcer 
avoided and 
net monetary 
benefit 
CEA: depend 
on threshold; 
CBA: not cost-
effective 
Robust (OW) 
Xakellis et al. 
[33]  
(UK and USA) 
1996 Prevention Aggressive 
interventive 
interventions based 
on 'Pressure ulcers in 
adults: prediction and 
No 
intervention 
CEA Prospective 
cohort study 
and 
retrospective 
data audit 
Not reported 
(health system) 
3 months* Cost per ulcer-
free day 
Cost-saving for 
higher risk 
groups 
NA 
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prevention. Clinical 
Practice Guideline, 
Vol 3' 
Xakellis et al. 
[34] 
(USA) 
1998 Prevention Aggressive 
interventive 
interventions based 
on 'Pressure ulcers in 
adults: prediction and 
prevention. Clinical 
Practice Guideline, No 
3' and 'Treatment of 
pressure ulcers. 
Clinical Practice 
Guideline, No 15' 
Before 
implementa
tion 
CEA Quasi-
experimental 
study 
Health care 
provider 
6 months* Cost per ulcer-
free day 
Cost-saving Variable (TW) 
CUA= cost-utility analysis; CEA=cost-effectiveness analysis; CBA= cost-benefit analysis; QALY= quality -adjusted life-year; OW=one-way; TW=two-way; SA= scenario analysis; PSA= probabilistic sensitivity analysis; NA= not 
applicable 
*Study period 
 11 
Table 3.Summary characteristics of economic evaluation studies for VLU 
Author 
(Setting) 
Publication 
Year 
Type of care Intervention Comparator Analysis Study design Perspective Time 
horizon/ 
Study 
period 
Outcome 
measures 
Baseline 
analysis 
Sensitivity 
analysis 
Bosanquet et 
al. [35] 
(UK) 
1993 Treatment New service 
provided by 
community leg 
clinics 
Standard care 
before the new 
services were set 
up 
CEA Quasi-
experimental 
study 
Not reported 
(health system) 
Not 
reported 
Annual costs and 
healing rate by 12 
weeks 
Cost-saving NA 
Korn et al. [36] 
(USA) 
2002 Prevention Compression 
stockings + 
education 
No prophylaxis CUA Markov model (4 
health states) 
Not reported 
(health system 
and societal) 
Life time Δcost/ΔQALY Cost-saving Robust (OW) 
McGuckin et 
al. [37] 
(UK and USA) 
2002 Diagnosis and 
treatment 
Care based on 
United States 
Guidelines for the 
Diagnosis and 
Treatment of 
Venous Leg 
Ulcers and the 
Oxfordshire 
Guideline for 
Venous Leg 
Ulcers 
Retrospective with 
no guidelines 
CEA Prospective cohort 
study and 
retrospective data 
audit 
Not reported 
(health system) 
Not 
reported 
Median costs and 
healing rate 
Cost-saving NA 
Simon et al. 
[38] (UK)  
1996 Prevention 
and treatment 
Community leg 
ulcer clinic 
includes 
assessment, 
compression 
therapy for 
treatment and 
prevention 
No coordinated 
attempt 
CEA Retrospective data 
audit 
Not reported 
(health system) 
13 weeks* The proportion of 
ulcerated limbs 
completely 
healed within 
three months and 
total cost of leg 
care 
Cost-saving NA 
CUA= cost-utility analysis; CEA=cost-effectiveness analysis; QALY= quality -adjusted life-year; OW=one-way; NA= not applicable 
*Study period 
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Table 4. Summary characteristics of economic evaluation studies for mixed types of chronic wounds 
Author 
(Setting) 
Publication 
Year 
Wound 
type 
Type of 
care 
Intervention Comparator Analysis Study design Perspective Time horizon/ 
Study period 
Outcome 
measures 
Baseline 
analysis 
Sensitivity 
analysis 
DaVanzo et 
al. [39] 
(USA) 
2010 DFU, PU, 
VLU, AU  
Treatment A specific 
structured, 
comprehensive 
wound 
management 
protocol provided 
by wound 
management team 
Did not receive 
protocol; did not 
receive care from 
wound management 
team 
CEA Retrospective 
data audit 
Medicare 10 months* Health care 
costs and 
clinical 
outcomes 
Cost-saving NA 
Graves et al. 
[40] 
(Australia) 
2014 DFU, VLU, 
AU, other 
ulcers 
Treatment 
and 
prevention 
Specialist clinic that 
follows evidence-
based care 
Retrospective phase: 
prior to the admission 
to the specialist clinic 
CUA Markov 
model (3 
health states) 
Not reported 
(health 
system) 
16 years  Δcost/ΔQALY Reduced 
cost 
Robust 
(PSA) 
Harris et al. 
[41] 
(Canda) 
2008 DFU, VLU, 
PU, other 
diabetic 
ulcers 
Treatment Specialty Service 
Alone that practice 
evidence-based 
care 
Minimal involvement of 
Specialty service with 
Registered Nurse and 
Registered Practical 
Nurse that practice 
current care 
CEA Retrospective 
data audit 
Not reported 
(health 
system) 
2 years 3 
months* 
Nursing visit 
costs and time 
to complete 
closure of 
chronic wounds 
Cost-saving NA 
Rybak et al. 
[42] 
(Poland) 
2012 Leg ulcers Treatment New treatment 
model based on 
EWMA guidelines 
Before implementation CEA Quasi-
experimental 
study 
Not reported 
(health 
system) 
30 weeks* Clinical 
outcomes and 
costs 
Cost-saving NA 
Vu et al. [43] 
(Australia) 
2007 leg ulcers 
and PU 
Treatment Multidisciplinary 
team + standard 
treatment protocol 
Usual care based on 
'The Residential Care 
Manual' 
CEA Pseudo-
randomized 
cluster trial 
Health system 20 weeks* Cost-saving per 
wound 
Cost-saving Robust 
(OW) 
DFU=diabetic foot ulcer; PU=pressure ulcer; VLU=venous leg ulcer; AU=arterial ulcer; CUA= cost-utility analysis; CEA=cost-effectiveness analysis; QALY= quality -adjusted life-year; OW=one-way; PSA= probabilistic 
sensitivity analysis; NA= not applicable; EWMA= European Wound Management Association 
*Study period 
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3.1.1 Diabetic Foot Ulcer (DFU) 
Ragnarson Tennvall et al. [24], Rauner et al. [25] and Wu et al. [27] developed Markov models to 
evaluate the cost-effectiveness of optimal prevention of DFU based on the International consensus 
on diabetic foot [44]. Ragnarson Tennvall et al. [24] and Rauner et al. [25] found that optimal 
prevention would not be cost-effective for low-risk groups, which were supported by one-way 
sensitivity analysis. ICER was reported as the primary outcome in those three studies, which enabled 
direct comparison with other studies. Cardenas et al. [21] also investigated the cost-effectiveness of 
optimal prevention but with a decision tree model. Although the study reported that optimal 
prevention was cost-saving, the decision tree only estimated results within 1 year. 
Optimal prevention and treatment of DFUs were assessed by Ortegon et al. [23], Rerkasem et al. 
[26] and Cheng et al. [22]. Rerkasem et al. [26] analysed retrospective audit data and reported that 
the Multidisciplinary Diabetic Foot Protocol was less expensive and gave patients a better quality of 
life. However, no sensitivity analysis was conducted to test the robustness of the outcome. Ortegon 
et al. [23] built a Markov model with comprehensive health states and estimated the cost-
effectiveness over a lifetime.  The authors only conducted one-way sensitivity analysis and did not 
identify any limitations but argued that the probability for bias was small. The study by Cheng et al. 
[22] is the only study that performed probabilistic sensitivity analysis (PSA) and provided information 
on how confident decision makers could be about the findings. They showed that optimal care 
always had a higher probability (around 85–95%) of being cost-effective compared with usual care 
regardless of the value of the willingness-to-pay threshold. But Cheng et al. [22] focused only on 
patients at high risk of DFUs. Moreover, although their study was conducted in an Australian setting, 
due to lack of local data, some model inputs were sourced from international studies. 
3.1.2 Pressure Ulcer (PU) 
All 8 included studies determined the cost-effectiveness of guideline-based prevention programs for 
PUs.  Three studies conducted before 2000 did not apply decision-analytic models [18, 33, 34]. Even 
though the three studies demonstrated that prevention programs were cost-saving, the quality was 
low due to short study period and lack of comprehensive sensitivity analysis. Whitty et al. [32] 
evaluated a care bundle using data collected from a cluster randomised trial.  They performed non-
parametric bootstrapping to derive the cost-effectiveness acceptability curve, which suggested that 
the point estimate was highly uncertain. On the other hand, Padula et al. [31] and Mathiesen et al. 
[30] applied decision analytic models and performed PAS to assess the probability of prevention 
programs being cost-effective. The time horizon used in these two studies, however, was short, less 
than 1 year. As a result, the studies might not be useful for long-term decision-making. 
Studies by Bayoumi et al. [28] and Makai et al. [29] provided strong evidence on the cost-
effectiveness of a PU prevention program. Bayoumi et al. obtained the effectiveness of the 
intervention from a systematic review and modelled costs and health outcomes associated with the 
intervention and control group over patients’ lifetimes. In addition, comprehensive sensitivity 
analysis was performed. With PSA, authors concluded that the certainty that alternative foam 
mattress with turning/repositioning strategies were economically attractive was moderate. Makai et 
al. [29] built a Markov model to extrapolate results from a one-year observational study to an 
additional year. They tested three scenarios in which effectiveness of evidence-based prevention 
measures were (1) not sustained, (2) partially sustained, and (3) completely sustained. Results from 
PSA indicated that there was great uncertainty when the effectiveness of prevention methods was 
not sustained or partially sustained in the future, which reflected scenarios that could happen in the 
real world.  
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3.1.3 Venous Leg Ulcer (VLU) 
As a model-based economic evaluation, Korn et al. [36] conducted a thorough literature review to 
derive the effectiveness inputs for the model. The authors also applied discounting to future costs 
and health benefits. The model was run over the lifetime of affected individuals, which informed a 
long-term outcome. The baseline results were found to be robust given the one-way sensitivity 
analysis. However, without a PSA, it is difficult to determine how confident decision makers can be 
about the findings. 
Bosanquet et al. [35], McGuckin et al. [37] and Simon et al. [38] did not develop economic models to 
extrapolate short-term findings beyond the study period. Neither did they conduct sensitivity 
analysis to test the uncertainty around parameters. When reporting the outcomes, they did not 
present the differences between groups. Moreover, limitations were not discussed in the study.   
3.2 Quality assessment 
Quality assessment of each study and reasons for a score of 0.5 are presented in Table 5. None of 
the 24 included studies addressed every item listed in the CHEERS reporting checklist. The 
compliance with the CHEERS checklist ranged between 43% and 83%. Studies published after 2013 – 
when CHEERS statement was available – had compliance of at least 63%.  
Time horizon refers to the period over which costs and consequences are being evaluated. For 
economic evaluations that were not model-based, the study period was extracted as the time 
horizon. Although most studies evaluated costs and health outcomes within a timeframe, only one 
study stated why their choice of time horizon was appropriate for the study [25]. 
Economic evaluations that were not model-based did not apply discounting to costs and health 
consequences. For model-based studies, 3 provided background for the choice of discount rate [21, 
22, 29]. Mathiesen et al. [30] did not use discount rate because of the short time horizon. The rest of 
the model-based studies either did not justify the choice of discount rate or did not report the use of 
discount rate. 
One thing worth noting is how measurement of effectiveness was obtained in each study. For 
economic evaluations that were not model-based, a score of 0.5 was given as they did not describe 
why the single study was a sufficient source of clinical effectiveness data. For model-based studies, 
three met the criteria with one conducting a systematic review [28] and two performing a thorough 
literature search [27, 36] to derive the effectiveness data for models , while the other 9 studies did 
not fully describe the methods used for identification of included studies and synthesis of clinical 
effectiveness data. 
Authors of model-based studies all prepared tables for parameter values used in the model. 
However, two studies did not report the range of values [23, 22]; two did not report the values for 
transition probabilities [25, 29] and one did not present the values nor the range of model inputs 
[40]. While most parameter estimates were sourced from published literature, two evaluations 
directly used data collected from an existing trial or study [29, 40].  With regards to the 
measurement and valuation of QoL outcomes, two studies derived utility estimates from population 
surveys [28, 40] and the remaining model-based evaluations used utility values from published 
literature. 
Sixteen studies conducted sensitivity analyses to test the uncertainty of input parameters. The most 
commonly used method was one-way sensitivity analysis where one input was varied between a 
minimum and a maximum value at a time. Six studies conducted PSA and presented how confident 
decision makers could be about the baseline results [22, 27, 28, 30, 31, 40]. However, not all 
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sensitivity analyses showed robust results. Xakellis et al. [34] found that the prevention strategy 
would be cost-saving except in the scenarios where treatment costs were reduced by an additional 
50%. Makai et al. [29] reported that if the effects from the prevention program could not be 
sustained, then the probability that the program was cost-effective would drop to 37% from 50% 
(totally sustained scenario). Only 4 studies characterized heterogeneity with 1 summarizing 
outcomes by age and risk groups [24], one evaluating cost-effectiveness for three age groups [22], 
one presenting ICERs for four risk groups [25] and 1 performing subgroup analysis by wound scores 
[33]. 
3.3 Usefulness of economic evaluations 
We judged the usefulness of included studies to decision making based on data extraction and 
reporting quality assessment, and categorized them into ‘strong’, ‘moderate’ or ‘limited’ level as 
shown in Table 6. Having a high compliance score to CHEERS reporting checklist does not necessarily 
guarantee that the study is of great use to decision making. 
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Table 5. Quality assessment using CHEERS statement 
 
Study (Publication year) Cardenas 
(2015) 
[21] 
Cheng 
(2017) 
[22] 
Ortegon 
(2004) 
[23] 
Ragnarson 
Tennvall 
(2001)[24] 
Rauner 
(2005) 
[25] 
Rerkasem 
(2009) 
[26] 
Wu 
(2018) 
[27] 
Bayoumi 
(2008) 
[28] 
Makai 
(2010) 
[29] 
Mathiesen 
(2013) 
[30] 
Padula 
(2011) 
[31] 
Thomson 
(1999) 
[18] 
1 Title 1 1 1 1 0.5a 0.5a 1 1 1 1 1 0.5a 
2 Abstract 0.5b 0.5c 1 0.5b 1 0.5b 1 1 0.5b 1 1 1 
3 Background and objectives 1 1 1 1 1 1 1 1 1 1 1 1 
4 Target population and subgroups 1 1 1 1 1 1 1 1 1 0 0 1 
5 Setting and location 1 1 1 1 1 1 1 1 1 1 1 1 
6 Study perspective 1 1 0 0 0 0 1 1 1 1 1 0 
7 Comparators 1 1 1 1 1 1 1 0.5d 0.5d 1 1 0.5d 
8 Time horizon 0.5e 0.5e 0.5e 0.5e 1 0.5e 0.5e 0.5e 0.5e 0.5e 0.5e 0.5e 
9 Discount rate 1 1 0.5e 0.5e 0.5e 0 1 0.5e 1 0.5f 0.5e 0 
10 Choice of health outcomes 0.5g 0.5g 0.5g 0.5g 1 0.5g 1 1 1 1 0.5g 1 
11 Measurement of effectiveness 0.5i 0.5i 0.5i 0.5i 0.5i 0.5h 1 1 0.5h 0.5i 0.5i 0.5h 
12 Measurement and valuation of 
preference-based outcomes 
NA NA NA NA NA 1 NA 1 NA NA NA NA 
13 Estimating resources and costs 1 1 1 1 1 1 1 1 1 1 1 1 
14 Currency, price date, and conversion 1 1 1 1 1 1 0.5s 0.5s 0.5s 1 1 0 
15 Choice of model 0.5j 1 1 1 1 NA 0.5j 0.5j 0.5k 0.5j 1 NA 
16 Assumptions 1 1 0 1 1 NA 1 1 1 1 1 NA 
17 Analytical methods 0.5u 0.5u 0.5u 1 0.5u NA 0.5u 1 0.5u 0.5u 1 NA 
18 Study parameters 1 0.5l 0.5l 1 0.5l 0 1 1 0.5l 1 1 0.5l 
19 Incremental costs and outcomes 0.5n 1 1 1 0 0.5m 1 0.5n 0.5n 1 1 0.5n 
20 Characterising uncertainty 0.5o 1 0.5o 0.5o 0.5o 0 1 1 1 1 1 0.5p 
21 Characterising heterogeneity 0 1 0 1 0 0 0 0 0 0 0 0 
22 Study findings, limitations, 
generalisability, and current knowledge 
1 1 0.5q 1 1 1 1 1 1 1 1 1 
23 Source of funding 1 0 0 0.5r 0 0.5r 0 0.5r 0 1 0 0 
24 Conflicts of interest 1 0 0 0 0 1 1 0 1 1 0 0 
 Compliance with the CHEERS checklist* 78% 78% 61% 76% 65% 57% 83% 79% 74% 80% 74% 53% 
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Table 5. Quality assessment using CHEERS statement (continued) 
 Study (Publication year) Whitty 
(2017) 
[32] 
Xakellis 
(1996) 
[33] 
Xakellis 
(1998) 
[34] 
Bosanquet 
(1993) 
[35] 
Korn 
(2002) 
[36] 
McGuckin 
(2002) 
[37] 
Simon 
(1996) 
[38] 
DaVanzo 
(2010) 
[39] 
Graves 
(2014) 
[40] 
Harris 
(2008) 
[41] 
Rybak 
(2012) 
[42] 
Vu 
(2007) 
[43] 
1 Title 1 1 1 1 0 0 0.5a 0.5a 0.5a 1 0.5a 1 
2 Abstract 1 0.5b 0.5b 0.5b 1 0.5b 0.5b 0.5b 0.5b 0.5b 0.5b 0.5b 
3 Background and objectives 1 1 1 1 1 1 1 1 1 1 1 1 
4 Target population and subgroups 1 1 1 1 1 1 1 1 1 1 1 1 
5 Setting and location 1 1 1 1 1 1 1 1 1 1 1 1 
6 Study perspective 1 0 1 0 0 0 0 1 0 0 0 1 
7 Comparators 1 1 1 0.5d 0.5d 1 0.5d 0.5d 0.5d 0.5d 1 0.5d 
8 Time horizon 0.5e 0.5e 0.5e 0 0.5e 0 0.5e 0.5e 0.5e 0.5e 0.5e 0.5e 
9 Discount rate 0 0 0 0 1 0 0 0 0 0 0 0 
10 Choice of health outcomes 1 1 1 0.5g 0.5g 1 0.5g 1 1 1 1 0.5g 
11 Measurement of effectiveness 0.5h 0.5h 0.5h 0.5h 1 0.5h 0.5h 0.5h 0.5h 0.5h 0.5h 0.5h 
12 Measurement and valuation of 
preference based outcomes 
NA NA NA NA NA NA NA NA 1 NA NA NA 
13 Estimating resources and costs 1 1 1 1 1 1 1 1 1 1 1 1 
14 Currency, price date, and conversion 1 0 0 1 1 0 1 1 0.5s 1 0 1 
15 Choice of model NA NA NA NA 0.5j NA NA NA 0.5j NA NA NA 
16 Assumptions NA NA NA NA 1 NA NA NA 1 NA NA NA 
17 Analytical methods NA NA NA NA 0.5u NA NA NA 0.5u NA NA NA 
18 Study parameters 0.5l 0.5l 0 0.5l 1 0.5l 0.5l 1 0 0.5l 0 0.5l 
19 Incremental costs and outcomes 1 0.5m 0 0.5m 1 0.5m 0.5m 1 1 1 0.5m 0.5m 
20 Characterising uncertainty 0.5t 0 1 0 1 0 0 0 1 0 0 0 
21 Characterising heterogeneity 0 1 0 0 0 0 0 0 0 0 0 0 
22 Study findings, limitations, 
generalisability, and current knowledge 
1 1 1 0.5q 0.5q 0.5q 0.5q 1 1 1 0.5q 1 
23 Source of funding 0.5r 0.5r 0.5r 0 0 0 0.5r 1 0.5r 0.5r 0 0.5r 
24 Conflicts of interest 0 0 0 0 0 0 1 1 0 0 0 1 
 Compliance with the CHEERS checklist* 73% 60% 60% 48% 65% 43% 55% 73% 63% 63% 45% 65% 
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a. did not identify the study as an economic evaluation or use more specific terms 
b. did not report uncertainty analysis 
c. did not include inputs 
d. did not explicitly mention the intervention was guideline-based 
e. did not state why 
f. did not use discount rate but gave reasons 
g. did not state the relevance 
h. did not state why the single study was a sufficient source of clinical effectiveness data 
i. did not describe the methods used for identification of included studies and synthesis of clinical effectiveness data 
j. did not give reasons for the specific type of decision-analytical model used 
k. did not give reasons for the specific type of decision-analytical model used nor show the model structure 
l. did not report values, ranges, references for all parameters 
m. did not report differences 
n. did not report mean values for the main categories of estimated costs and outcomes of interest 
o. not all input parameters were tested for uncertainty 
p. did not separate sensitivity analysis from baseline analysis 
q. did not discuss limitations 
r. did not describe the role of the funder in the identification, design, conduct, and reporting of the analysis 
s. did not include reference year 
t. applied non-parametric bootstrapping 
u. only applied face validation of the model or no validation 
NA=not applicable 
*Fully meeting the criteria contributed 1 to the numerator and partially meeting the criteria contributed 0.5 to the numerator 
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Table 6. Usefulness of reviewed studies to decision making 
 
Study Level of usefulness Primary reasons 
Bayoumi et al. [28] Strong Life-time horizon; applied model calibration and full sensitivity 
analysis 
Cardenas et al. [21] Moderate Outcome measures used; lack of probabilistic sensitivity 
analysis 
Cheng et al.[22]  Moderate Lack of appropriate model validation; no indirect costs 
Ortegon et al. [23] Moderate Lack of probabilistic sensitivity analysis; no indirect costs 
Ragnarson Tennvall et al. [24] Moderate Lack of probabilistic sensitivity analysis; no indirect costs 
Rauner et al. [25] Moderate Lack of probabilistic sensitivity analysis; no indirect costs 
Wu et al. [27] Moderate Lack of appropriate model validation; no indirect costs 
Makai et al. [29] Moderate Lack of appropriate model validation; no indirect costs 
Mathiesen et al. [30] Moderate Time horizon and outcome measures used; no indirect costs 
Whitty et al. [32] Moderate Lack of probabilistic sensitivity analysis; short time horizon 
Korn et al. [36] Moderate Lack of probabilistic sensitivity analysis 
Graves et al. [40] Moderate Lack of appropriate model validation; no indirect costs 
Vu et al. [43] Moderate Lack of probabilistic sensitivity analysis; short time horizon 
Rerkasem et al. [26] Limited Study design; lack of sensitivity analysis 
Padula et al. [31] Limited One-year time horizon but included QALYs over remaining life 
expectancy as final reward 
Thomson et al. [18] Limited Study design; lack of probabilistic sensitivity analysis 
Xakellis et al. [33]  Limited Outcome measures used; short time horizon; no indirect costs 
Xakellis et al. [34] Limited Outcome measures used; short time horizon; no indirect costs 
Bosanquet et al. [35] Limited Different time frame for costs and health outcomes; lack of 
sensitivity analysis 
McGuckin et al. [37] Limited Outcome measures used; lack of sensitivity analysis; no indirect 
costs 
Simon et al. [38]  Limited Lack of sensitivity analysis; short time horizon; no indirect costs 
DaVanzo et al. [39] Limited Lack of sensitivity analysis; short time horizon; no indirect costs 
Harris et al. [41] Limited  Outcome measures used; lack of sensitivity analysis 
Rybak et al. [42] Limited Lack of sensitivity analysis; short time horizon; no indirect costs 
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4 DISCUSSION 
We reviewed existing full economic evaluation studies of guideline-based care and found that 
guideline-based care may be cost-saving or cost-effective in most circumstances. In other words, 
providing better wound management based on guidelines would improve patient outcomes at a 
lower cost or at some acceptable additional cost. In the absence of perfect information, those 
economic evaluation studies can give decision makers the confidence to promote guideline-based 
care. However, the level of confidence varies greatly by the study design and the quality of economic 
evaluations.  
4.1 General issues 
4.1.1 Time horizon 
Researchers tended to report short-term results if they simply analysed data from retrospective data 
audit, before/after study, or randomised controlled trials. They often chose healing as the event of 
interest and endpoint. But chronic wounds are highly likely to recur. Studies with a short time 
horizon would fail to capture benefits or identify losses in the future. As a result, information 
generated from this type of economic evaluation is of limited use to decision makers to incorporate 
into long-term planning.  
4.1.2 Perspective and indirect cost 
Some studies did not state what economic perspective the studies were based on. The perspective 
of an economic evaluation plays an important role, because it determines whether the study should 
include the impact of a program on the whole society or just on those directly involved. Failure to 
report the perspective again limited the usefulness of these studies to decision makers. Most studies 
were conducted from a health system perspective and calculated the direct costs to the health 
system. However, omitting indirect cost such as patient out-of-pocket costs would fail to inform 
whether the decision to adopt a certain policy would benefit the whole society. Only four studies 
were conducted from a societal perspective [21, 36, 31, 26] and three of them included opportunity 
costs from lost productivity [21, 36, 26]. One study claimed to use a societal perspective but simply 
assumed additional 25% unforeseen costs [31]. 
4.1.3 Sensitivity analysis 
The level of confidence in economic evaluation studies can be boosted by sensitivity analyses. In this 
review, we found that 14 out of 22 included studies performed sensitivity analysis to test the 
uncertainty around study variables. Studies that performed PSA provided the strongest evidence on 
the robustness of study findings, since PSA explicitly demonstrates the probability that a program is 
cost-effective. Decision makers would find this type of information useful when they want to avoid 
investing in programs that are unlikely to be good value for money. 
4.1.4 Wound types 
In this systematic review, we also found that the level of evidence varies by wound type. There is 
strong evidence showing that guideline-based care for DFU and PU is cost-effective or cost-saving, 
while evidence is weak in terms of guideline-based care for VLU. We identified 4 studies that 
evaluated health outcomes and costs of implementing good practice for VLU, but those studies are 
not up-to-date and the quality is not satisfactory. Moreover, although AU is one type of chronic 
wound, we couldn’t identify any study that specifically conducted economic evaluation of guideline-
based care for AU. Thus, more economic evaluation studies are required to raise the evidence level. 
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4.2 Model-based studies 
Several studies in this review applied Markov models to estimate long-term patient outcomes and 
costs. It seems that model-based economic evaluation fully described the disease progression and 
provided better information. But not all model-based economic evaluations attained satisfactory 
quality scores.   
4.2.1 Model structure and assumption 
When modelling techniques are applied to healthcare decision making, it has been recommended 
that models represent disease processes appropriately and addresses the decision problem [45]. Of 
the 12 reviewed model-based studies, health states or clinical events closely related to ulcer 
progressing and costs were modelled and presented clearly in figures in most studies. But one study 
only summarized transitions between health states in tables [25] and one study did not provide any 
table or figure for model structure [29]. Assumptions around model structure have an impact on 
model prediction. For example, studies that used Markov model to evaluate cost-effectiveness of 
managing DFU all assumed that patients would not develop another ulcer or have amputation after 
one major amputation. The assumption may be reasonable for models with shorter time horizon. 
But for models with a lifetime time horizon [23, 27], the total costs of managing DFU could be 
underestimated as it is possible for patients to experience recurrence and another amputation. 
4.2.2 Model validation and calibration 
Comprehensive validation and calibration could help improve accuracy and credibility of decision-
analytic models [45]. But a lack of model validation and calibration was observed among model-
based economic evaluations reviewed in this study despite the recommendations on reporting 
model performance evaluation. Two studies did not provide information on validation of their 
Markov models probably because the models were built based on trial data [29, 40]. One study 
applied internal validation, comparing ulcer incidence and amputation incidence derived from the 
model with numbers used as model inputs [23]. Two studies conducted external validation by 
comparing model outputs with observations that were not used in model development[24, 31]. One 
study performed calibration to ensure that the input incidence produced observed prevalence [28]. 
The other 8 studies applied basic face validity such as comparing model outputs with other 
published studies to justify their results were sensible. 
4.2.3 Quality of model inputs 
Although economic evaluation is not expected to produce perfect prediction of future costs and 
health outcomes, the use of poor-quality data sources will lead to concerns over the credibility of 
model outputs. All model-based studies reviewed conducted the evaluation within the national 
setting. However, lack of local data sources was identified as a limitation in almost all studies that 
resorted to international literature to some extent. Using epidemiological, costs or QoL parameters 
generated from a different population as key model inputs may lead to underestimation or 
overestimation of health outcomes and costs. Another issue related to the quality of model inputs is 
data synthesis. For models built on a single trial, the issue is whether the single study acts as 
sufficient source of data. Markov models are data driven, usually requiring synthesis of data from 
different sources. We found that only 3 studies fully describe the methods used for identification of 
included studies and synthesis of clinical effectiveness data [27, 28, 36]. Key epidemiological and 
clinical parameters used in model-based studies often originated from sources of varying quality, 
ranging from experimental studies to expert opinion. 
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4.3 Limitations 
This review has four main limitations. First, we may have missed some economic evaluation studies 
despite the use of broad search terms. Second, our findings may be subject to publication bias as 
significant results are more likely to be published. It might be more difficult to publish studies that 
report that guideline-based wound care was not cost-effective or cost-saving or the authors might 
be less willing to submit these results for publication. Thus, readers should bear in mind that it is 
possible that guideline-based care may not always bring economic benefits. Third, we assessed the 
quality of studies and strength of evidence based on judgment. Finally, our assessment of study 
quality using the CHEERS checklist may reflect the way evaluations are reported rather than 
conducted. Therefore, the conclusions should be interpreted with caution. 
 
5 CONCLUSION 
The economic evaluation studies identified by this systematic review suggested that adopting 
guideline-based care may be a cost-effective or cost-saving strategy for patients affected by chronic 
wounds. There are variations in the quality of studies and the information presented is not always 
useful to assist decision making. Better information and higher-quality studies may increase decision 
makers' confidence to promote guideline-based wound care in the future. We also suggest that 
future economic evaluations in this field conform more closely to CHEERS reporting guidelines. 
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